Fanconi anemia is a genetic disease characterized by genomic instability and cancer predisposition 1 . Nine genes involved in Fanconi anemia have been identified; their products participate in a DNA damage-response network involving BRCA1 and BRCA2 (refs. 2, 3) . We previously purified a Fanconi anemia core complex containing the FANCL ubiquitin ligase and six other Fanconi anemiaassociated proteins [4] [5] [6] . Each protein in this complex is essential for monoubiquitination of FANCD2, a key reaction in the Fanconi anemia DNA damage-response pathway 2,7 . Here we show that another component of this complex, FAAP250, is mutant in individuals with Fanconi anemia of a new complementation group (FA-M). FAAP250 or FANCM has sequence similarity to known DNA-repair proteins, including archaeal Hef, yeast MPH1 and human ERCC4 or XPF. FANCM can dissociate DNA triplex, possibly owing to its ability to translocate on duplex DNA. FANCM is essential for monoubiquitination of FANCD2 and becomes hyperphosphorylated in response to DNA damage. Our data suggest an evolutionary link between Fanconi anemiaassociated proteins and DNA repair; FANCM may act as an engine that translocates the Fanconi anemia core complex along DNA.
Fanconi anemia is a genetic disease characterized by genomic instability and cancer predisposition 1 . Nine genes involved in Fanconi anemia have been identified; their products participate in a DNA damage-response network involving BRCA1 and BRCA2 (refs. 2,3) . We previously purified a Fanconi anemia core complex containing the FANCL ubiquitin ligase and six other Fanconi anemiaassociated proteins [4] [5] [6] . Each protein in this complex is essential for monoubiquitination of FANCD2, a key reaction in the Fanconi anemia DNA damage-response pathway 2, 7 .
Here we show that another component of this complex, FAAP250, is mutant in individuals with Fanconi anemia of a new complementation group (FA-M). FAAP250 or FANCM has sequence similarity to known DNA-repair proteins, including archaeal Hef, yeast MPH1 and human ERCC4 or XPF. FANCM can dissociate DNA triplex, possibly owing to its ability to translocate on duplex DNA. FANCM is essential for monoubiquitination of FANCD2 and becomes hyperphosphorylated in response to DNA damage. Our data suggest an evolutionary link between Fanconi anemiaassociated proteins and DNA repair; FANCM may act as an engine that translocates the Fanconi anemia core complex along DNA.
We previously showed that seven of nine components of the Fanconi anemia core complex are Fanconi anemia-associated proteins (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG and FANCL) [4] [5] [6] . Using mass spectrometry, we identified another component, FAAP250 (Fig. 1a) , as KIAA1596, a hypothetical protein with unknown function. Antibodies raised against KIAA1596 specifically recognized the 250-kDa polypeptide of the Fanconi anemia core complex immunopurified by a FANCA antibody, supporting the conclusion that KIAA1596 is FAAP250 (Fig. 1b) .
Several lines of evidence suggest that FAAP250 is an integral component of the Fanconi anemia core complex. First, we detected FAAP250 in the Fanconi anemia core complex immunoisolated by an antibody to Flag from cells expressing either Flag-tagged FANCA or Flag-tagged FANCL (Fig. 1b) . Second, FAAP250 was coimmunoprecipitated by antibodies against multiple Fanconi anemia core complex components (FANCA, FANCC and FANCF) from lymphoblastoid cells of a normal individual but not those from individuals with Fanconi anemia deficient in the corresponding Fanconi anemiaassociated proteins (Fig. 1c) . Third, reciprocal immunoprecipitation in HeLa cells using the FAAP250 antibody showed coprecipitation of multiple Fanconi anemia core complex components, such as FANCL, FANCA and FANCG ( Fig. 1d and data not shown).
Depletion of FAAP250 in HeLa and HEK293 cells by short interfering RNA (siRNA) markedly reduced the levels of monoubiquitinated FANCD2 both under basal conditions and after induction with mitomycin C (MMC; Fig. 2a and data not shown), similar to depletion of other core complex components 5, 6, 8 . Cells depleted of FAAP250 also showed increased MMC sensitivity ( Supplementary  Fig. 1 online) , like Fanconi anemia cells. We infer that FAAP250, like the other core complex components, has an essential function for FANCD2 monoubiquitination and that the corresponding gene probably underlies a distinct Fanconi anemia complementation group.
A long form of FAAP250 (FAAP250-L) was induced when cells were treated with MMC, hydroxyurea and cisplatin (Fig. 2a,b and data not shown), implying that FAAP250 is post-translationally modified in response to DNA damage or replication block. FAAP250-L was also detected when Fanconi anemia cells deficient in FANCA, FANCB, FANCE and FANCL were treated with MMC ( Fig. 2c and data not shown), suggesting that this modification occurs independently of the ubiquitin ligase activity of the Fanconi anemia core complex. When treated with a phosphatase, both short (FAAP250-S) and long (FAAP250-L) forms of FAAP250 showed increased mobility on SDS gels (Fig. 2d) , suggesting that FAAP250 is a phosphoprotein that becomes hyperphosphorylated in response to genotoxic stress.
FAAP250 has a single homolog in other vertebrate species. It contains two potential enzymatic domains: one homologous to a superfamily of DEAH-box helicases or DNA-stimulated ATPases; the other homologous to the endonuclease domain of ERCC4 (also called XPF; Fig. 3 ). FAAP250 is closely related to archaeal protein Hef (E value ¼ 10 À43 ), which possesses both helicase and endonuclease activities and can resolve stalled replication forks 9, 10 . Hef has also been proposed to be the archaeal homolog of ERCC4 (refs. 11,12) , an endonuclease essential for nucleotide excision repair in eukaryotes 13, 14 . FAAP250 and ERCC4 are the only proteins in the human genome with a helicase-ATPase domain at the N terminus and an endonuclease domain at the C terminus, suggesting that they may have a common ancestor.
Although the helicase-ATPase domains of FAAP250 proteins are highly conserved in the seven motifs present in the SF2 family of helicases ( Supplementary Fig. 2 online) , their endonuclease domains are degenerate at several residues that are absolutely conserved in ERCC4 and the Mus81 family of endonucleases 15 ( Supplementary  Fig. 3 online) . Mutation of the corresponding residues in ERCC4 either inactivates or strongly reduces its endonuclease activity 15 . It seems likely that during evolution, the nuclease domains of FAAP250 proteins may have diverged, becoming dispensable and nonfunctional. 
de-P- Proteins with high homology to the helicase domains of FAAP250 are present in other eukaryotic species such as fruit flies (CG7922) and yeast (MPH1; E values ¼ 10 À78 and 10 À60 , respectively). These proteins may have the same antecedents as FAAP250 but experienced the loss of nuclease domains during evolution. MPH1 protein has a DNA helicase activity 16 and participates in an error-free DNA-damage bypass pathway to protect the genome from spontaneous and chemically induced damage 17, 18 . The similarity between FAAP250 and MPH1 suggests that they may be part of common mechanisms that guard genome stability. The helicase domains of ERCC4 are also degenerate and perhaps nonfunctional 11, 12 ( Supplementary Fig. 2 online) . Thus, FAAP250 and ERCC4 may have derived from a common ancestor that, like archaeal Hef, has both functional helicase and nuclease domains. They may have subsequently diverged, with ERCC4 retaining its endonuclease activity and FAAP250 maintaining its helicase-ATPase activity.
To assess possible biochemical activity of FAAP250, we generated cell lines that stably express FAAP250 tagged with a Flag epitope and immunoisolated the tagged protein using the Flag antibody (Fig. 4a) . As a control, we made a point mutant by substituting arginine for a conserved lysine in the helicase motif I (Supplementary Fig. 2 online and Fig. 4a ). This substitution in other helicase domains completely inactivates ATPase and helicase activities 19, 20 . Consistent with previous data, the wild-type FAAP250 protein, but not the mutant, had singleand double-stranded DNA-stimulated ATPase activity (Fig. 4b) . The fact that the mutant protein had no detectable ATPase activity indicates that this activity is derived from the helicase domain of FAAP250.
FAAP250 had no detectable helicase activity in strand-displacement assays using substrates consisting of double-stranded DNA, four-way junction or replication fork, which can be resolved by either MPH1 or Hef 10, 16 ( Fig. 4c and Supplementary Fig. 4 online) . The absence of detectable helicase activity in FAAP250 argues that it may function differently from MPH1 and Hef. But we cannot rule out the possibility that FANCM may be a structure-specific helicase, and the absence of a detectable helicase activity could be due to lack of normal physiological environment in our assays.
Many proteins with SF2 helicase domains can use the energy of ATP hydrolysis to translocate on DNA [21] [22] [23] . One way to demonstrate translocase activity is the triple-helix displacement assay. In this assay, a triple helix is formed in which each nucleotide of the third strand forms Hoogsteen base pairs with Watson-Crick base pairs of the duplex. When the translocase proceeds through the triplex, it 4 were used as a positive control. The DNA substrate has 13-nucleotide single-stranded tails on both sides of a 20-bp double-stranded region, and so it should be able to detect activity of helicases of either 5¢-to-3¢ or 3¢-to-5¢ directions. (d) Autoradiograph showing that Flag-FAAP250 has a triple-helix unwinding activity, whereas its ATPase mutant (K117R) lacks such activity. A chromatin-remodeling complex, ATRX complex 30 , was used as a positive control. The substrate consists of a 40-base homopyrimidine oligonucleotide located centrally on a 190-bp double-stranded DNA 23 . (e) Autoradiograph showing that Flag-FAAP250 does not displace a blunt triple helix. The substrate is the same as in d, except that the duplex DNA is the same size (40 bp) as the homopyrimidine oligonucleotide to create the blunt triplex. The band with faster mobility is from the designed blunt triplex substrate. The band with slower mobility (marked with an arrowhead) is from the precursor of the substrate. The asterisks in c-e indicate the positions of the radioactively labeled 32 P in each DNA substrate. Supplementary Figures 2 and 3 online. The marked domains (X) are predicted to be nonfunctional based on degeneracy of their sequences compared with the consensus. The helicase domains of ERCC4 proteins have been suggested to be degenerate and perhaps nonfunctional 11, 12 . The E values were obtained by searching the National Center for Biotechnology Information database with the BLASTP program and human FANCM as the query sequence. The homology between MPH1 and a partial expressedsequence tag sequence of FAAP250 has been described 17 . 
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displaces the third strand. Wild-type FAAP250, but not the mutant, had triple-helix displacement activity (Fig. 4d) . To exclude the possibility that FAAP250 could displace the triplex through direct binding and dissociation, we used a blunt triplex in this assay and found that FAAP250 failed to displace this substrate (Fig. 4e) . Taken together, these results suggest that FAAP250 can dissociate DNA triplex, possibly owing to an ability of the protein to translocate on duplex DNA. We screened cells derived from individuals with Fanconi anemia for FAAP250 mutations by immunoblotting. We detected FAAP250 in cells from individuals with all known complementation groups ( Fig. 5a and data not shown), implying that if FAAP250 is mutant in individuals with Fanconi anemia, this would constitute a new complementation group. FAAP250 was undetectable in a cell line from individual EUFA867 who was excluded from many known complementation groups (A, B, C, E, F and G) by linkage analysis, cell fusion and cDNA transfection (data not shown). Sequencing of this individual's cDNA identified a nonsense mutation (2171C-A, resulting in the amino acid substitution S724X) in exon 13 and the absence of the sequence encoded by exon 15, caused by a 2,554-bp deletion spanning part of intron 14 and almost all of exon 15 ( Fig. 5b and Supplementary Fig. 5 online) . In theory, these mutations could lead to truncated products of 80 kDa and 160 kDa, respectively, but neither product was detectable (data not shown), suggesting that they may be unstable.
Another individual with Fanconi anemia in the same family, a sibling of individual EUFA867, has the identical mutations in his blood DNA, providing additional evidence that mutant FAAP250 underlies Fanconi anemia in these individuals. We detected the nonsense mutation in DNA from blood and from a lymphoblastoid cell line of the siblings' healthy mother, consistent with maternal inheritance of this allele. We did not detect the genomic deletion in DNA from blood or a lymphoblastoid cell line of their healthy father, but linkage analysis with tightly linked flanking markers (D14S259 and D14S1027) showed that both siblings had inherited the same paternal allele, and correct paternity was established with multiple markers (data not shown). Because it is unlikely that the same deletion has occurred independently twice in individual EUFA867 and her sibling, the most likely explanation is that the father is mosaic for this deletion: his germ cells, but not blood cells, carry the mutation, which was thus transmitted to his children. In summary, our results show that FAAP250 is mutant in individuals with a new Fanconi anemia complementation group (FA-M); therefore, we called the gene encoding FAAP250 FANCM.
Numerous attempts to use FANCM cDNA to complement FA-M cells (from individual EUFA867) for MMC sensitivity (Supplementary Fig. 1 online) and defective FANCD2 monoubiquitination failed. The main reason is that we were unable to ectopically express FANCM in these cells using either plasmid and viral vectors with either constitutive or inducible promoters. As an alternative, we used other approaches to evaluate the importance of FANCM in the Fanconi anemia core complex and pathway. First, FA-M cells had markedly reduced levels of FANCA and FANCG and modestly reduced levels of FANCL (Fig. 5c) , like Fanconi anemia cells lacking FANCA or FANCB, in which the levels of FANCG and FANCL are correspondingly reduced. The fact that FANCA and FANCG are unstable in FA-M cells underscores the importance of FANCM for the integrity of the core complex. Second, FA-M cells had deficient nuclear localization of FANCA and FANCL (Fig. 5d) , a characteristic also observed in FA-B cells. Third, the interaction between FANCM and FANCA was defective in Fanconi anemia cells lacking other core complex components (Fig. 5e,f) , and the interaction between FANCM and FANCL was absent in FA-A and FA-B cells (Fig. 5f) , providing additional evidence that FANCM is part of the core complex.
Notably, FA-M cells were defective in FANCD2 monoubiquitination (Fig. 5c) , a common feature of all cells from individuals with Fanconi anemia with a mutant core complex component. This result is also consistent with siRNA data in HeLa and HEK293 cells showing that depletion of FANCM markedly reduced levels of monoubiquitinated FANCD2 (Fig. 2a and data not shown) . Taken together, these data indicate that FANCM, like the other seven Fanconi anemia core complex proteins, is necessary for Fanconi anemia core complex assembly and FANCD2 monoubiquitination. Although Fanconi anemia-associated proteins have been implicated in DNA repair, the interactions between these proteins and DNA are poorly understood, because these proteins lack DNA-related enzymatic domains or activities. Here we show that FANCM has a conserved helicase domain and a DNA translocase activity. Another Fanconi anemia-associated protein, FANCJ, was recently identified as BACH1 or BRIP1 (ref. 24 ), a known DNA helicase 25 . The identification of two Fanconi anemia-associated proteins with helicase domains or activities suggests that these proteins participate directly in a mechanism of DNA repair.
We propose that FANCM may have at least three roles in this process. First, it may have a structural role to allow assembly of the Fanconi anemia core complex, because in its absence, the nuclear localization and stability of several Fanconi anemia-associated proteins are defective (Fig. 5c,d) . Second, FANCM may act as an engine that translocates the core complex along DNA. Speculatively, this translocation may allow the core complex to sense and locate to the damaged DNA, which could be an important step either before or after FANCD2 monoubiquitination. Third, FANCM is hyperphosphorylated in response to DNA damage, suggesting that it may serve as a signal transducer through which the activity of the core complex is regulated. A DNA damage checkpoint kinase, ATR, has been shown to act upstream of the Fanconi anemia pathway 26, 27 , but its substrate has not been defined. FANCM contains multiple predicted ATR phosphorylation sites (data not shown) and may serve as a substrate through which ATR regulates FANCD2 monoubiquitination.
In contrast to FANCM, which acts upstream of the Fanconi anemia pathway (in terms of FANCD2 monoubiquitination) and has no helicase activity, FANCJ functions downstream 28 and possesses a 5¢-to-3¢ helicase activity 25 . FANCJ may directly repair damaged DNA with this activity. It remains to be determined how the function of FANCJ is connected to the Fanconi anemia pathway. Notably, BLM, a helicase with 3¢-to-5¢ polarity (opposite of FANCJ), associates with FANCM ( Fig. 1d) and the rest of the Fanconi anemia core complex 4 . The presence of three proteins with distinct helicase properties in the Fanconi anemia-related complexes suggests a coordinated action of Fanconi anemia-associated proteins in DNA repair.
METHODS
Cell lines. We established Epstein Barr virus-immortalized lymphoblastoid cell lines from blood samples from individual EUFA867 with Fanconi anemia and her parents, who had been referred to the EUFAR cell repository for genetic subtyping. The research was carried out after approval by the Guy's Hospital Research Ethics Committee (London) and the Institutional Review Board (VU University Medical Center, Amsterdam). We obtained informed consent from all human subjects involved in our work. We cultured cell lines in RPMI medium with 10% fetal calf serum.
Protein purification and analysis. We immunopurified Fanconi anemia core complex with a FANCA antibody from HeLa cells as described 4 . We identified FAAP250 by liquid chromatography-mass spectrometry analysis. The mass spectrometry data are available on request. We made two polyclonal rabbit antibodies (FAM-1Ab and FAM-2Ab) against FAAP250 (FANCM) by using two chimeric proteins containing regions of FAAP250 (amino acids 1,190-1,273 and amino acids 1,643-2,048, respectively) fused to maltose-binding protein as immunogen. These fusion proteins were expressed and purified from Escherichia coli in accordance with the manufacturer's protocols (New England Biolabs) and used for immunization as well as for purification of the antibody. Immunoprecipitation conditions were as described 4 . We prepared nuclear and cytoplasmic extracts as described 4 .
Immunoprecipitation and dephosphorylation of FANCM. We either treated HEK293 cells with hydroxyurea for 24 h or left them untreated and then extracted them with lysis buffer (50 mM Tris-HCl (pH 7.5), 300 mM NaCl, 1% Triton X-100 and 1 mM dithiothreitol) supplemented with a protease inhibitor cocktail (Roche) and phosphatase inhibitors (50 mM NaF and 2 mM Na 3 VO 4 ). We immunoprecipitated FANCM using FAM-1Ab. We washed the immunoprecipitate twice with l phosphatase buffer (New England Biolabs) and resuspended it in 50 ml of l phosphatase buffer either in the presence or absence of phosphatase inhibitors. We added 400 units of l phosphatase (New England Biolabs) to each sample and then incubated them at 30 1C for 1 h. We separated samples by 6% SDS-PAGE and immunoblotted them for FANCM using FAM-1Ab antibody.
Cloning of FANCM and construction of vectors. We purchased a KIAA1596 cDNA clone from Origen Inc. Sequencing showed that this clone contains an open reading frame of 2,048 amino acids, longer than the predicted sequence of XP_048128 (2,014 amino acids) at National Center for Biotechnology Information. We subcloned the cDNA by standard molecular biology techniques into mammalian expression vectors, pCEP4 and pMEP4 (InVitrogen), linked the cDNA with the Flag epitope at the N terminus and cloned it into pIRESneo3 vector (Clonetech). We also cloned the Flag-tagged FANCM cDNA into the pCEP4 vector and the retroviral vector using the Gateway recombinant DNA system (InVitrogen). These constructs were used for complementation and expression studies.
Transfection and complementation. We transfected HeLa cells using siRNA oligonucleotides as described 5 . The FANCM siRNA oligo used two different 19-nucleotide target sequences and was purchased from Dharmacon Research. We transfected HEK293 cells with Flag-tagged FANCM cDNA in a pIRESneo3 vector and selected them for G418-resistant clones. We screened these clones for expression of Flag-FANCM by immunoblotting. Those clones expressing high levels of Flag-FANCM were grown in large scale for immunopurification of the protein. We transfected the cell line from individual EUFA867 with pIRESneo3, pCEP4 and pMEP4 vectors containing FANCM cDNA and selected them on medium containing either G418 (0.4 mg ml À1 ) or hygromycin (0.1 mg ml À1 ). For inducible expression of FANCM in EUFA867 cells, we used the GeneSwitch system (InVitrogen). We determined cross-linker sensitivity for EUFA867 cells using a MMC-induced growth inhibition assay as described 6 . We carried out the MMC sensitivity assay for FANCM-depleted HeLa cells as described 29 , with the following modifications. We transfected HeLa cells with either a FAAP250 siRNA oligo or a control oligo and grew them for 60 h. We then plated them at a density of 500 cells per 10-cm dish. After 8 h, we treated cells with MMC at the indicated concentration ( Supplementary  Fig. 1 online) for 2 h. We then washed away the drug and added fresh medium. After 9-12 d, we fixed, stained and counted the colonies. We determined FANCM expression by either direct immunoblotting or by immunoprecipitation-coupled immunoblotting.
Biochemical analysis of FANCM. We immunoisolated Flag-tagged wild-type and mutant FANCM proteins from HEK293 cell clones selected for high expression. The protocols were essentially as described 5 , except the nuclear extract was depleted with a BLM antibody before immunoprecipitation with the Flag antibody. We did this because FANCM, like the other Fanconi anemia core complex components, stably associates with the BLM helicase and topoisomerase IIIa, so that if Flag-FANCM is immunoisolated directly from the extract, the intrinsic helicase activity of BLM is high enough to interfere with our analysis of the FANCM activity. We therefore thoroughly depleted BLM until the Flag-FANCM ATPase mutant protein (K117R) had no detectable ATPase activity. The Flag-FANCM fraction that we obtained contained low levels of Fanconi anemia core complex, as indicated by presence of other Fanconi anemia core complex components by western blotting (data not shown). But most Flag-FANCM did not seem to be assembled into the core complex, possibly owing to overexpression of the exogenous protein (which is at least tenfold higher than that of the endogenous protein; data not shown). We then analyzed the Flag-FANCM proteins that we obtained for ATPase, helicase and triple-helix unwinding activities as described 4, 23, 30 . We used B50 ng of Flag-FANCM in the different assays. The final concentration of ATP in the ATPase assay is 1 mM. The reaction was incubated for 30 min at 30 1C. Two DNA duplex substrates ( Supplementary Fig. 4 online) containing 40-nucleotide single-stranded DNA tails at either the 5¢ or the 3¢ end of the duplex region used the exact sequences as described 16 .
Amplification of FANCM sequences. We isolated total RNA from lymphoblastoid cell line EUFA867 using a Qiagen RNeasy kit (Qiagen). We prepared cDNA using 10 pmol oligo-dT 20 primers and Superscript II RT polymerase (Invitrogen). We carried out the PCR reactions for amplification of FANCM on cDNA using Platinum Taq polymerase (Invitrogen) and primers that covered the whole cDNA sequence. We isolated genomic DNA from whole blood and lymphoblastoid cell lines of affected individuals and family members using a Qiagen Blood mini kit (Qiagen). We carried out the PCR reactions for amplification of exon 13 of FANCM on 200 ng of genomic DNA using Platinum Taq polymerase (Invitrogen) and primers in intron 12 and 13. The deletion-containing region of the genomic DNA was amplified using Pfx polymerase (Invitrogen) and primers in intron 14 and 16.
Sequencing of FANCM. We purified PCR products using a SAP/EXO treatment (Amersham Biosciences) in accordance with the manufacturer's instructions. Sequencing reactions were prepared using 10 pmol of primer and Big Dye terminator cycle sequencing kit (Applied Biosystems) and carried out with the GeneAmp PCR system 9700 (Applied Biosystems). We analyzed samples on an ABI 3730 DNA Analyzer (Applied Biosystems). Note: Supplementary information is available on the Nature Genetics website.
